Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 35

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
 with MHKDG and RCT. Royalties will be recognized in the condensed consolidated statements of operations and comprehensive loss when net sales are recognized.

Note 17 - Segment Information

The Company operates as a single operating segment, focusing exclusively on the research, development, and eventual commercialization of its product. As the entire Company is centered around these activities, all consolidated parts of the Company are reviewed and analyzed as part of one segment.

28

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

As of June 30, 2025, the Company's single operating segment had not generated revenue from any programs or services. The accounting policies of the segment are the same as those described in the Note 2 — Basis of Presentation and Significant Accounting Policies section. The measure of segment assets is reported on the unaudited condensed consolidated balance sheets as total assets. The measure of segment profit or loss is reported on the unaudited condensed consolidated statement of operations as net loss. The CODM uses this as a starting point alongside significant non-cash items and working capital changes to evaluate cash burn and determine financial sustainability, cost management patterns and overall business viability as the clinical trials progress. The CODM also uses this to manage operations and ensure the most efficient use of Company resources against current budgets, alignment with strategic goals and preparation of future forecasts. Significant Segment ExpensesThe measure of significant segment expenses is reported in the accompanying unaudited condensed consolidated statements of operations as “Research and development” and “General and administrative” for the six months ended June 30, 2025 and 2024.Non-cash share-based compensation is reported in Note 14 — Share-Based Compensation for the six months ended June 30, 2025 and 2024. Non-cash depreciation and amortization for the six months ended June 30, 2025 and 2024 was $1.1 million and $0.7 million, respectively.Geographical DataLong-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of June 30, 2025 and December 31, 2024 are as follows:(in thousands)CountryJune 30, 2025December 31, 2024Switzerland$468 $610 United Kingdom1,295 1,777 Portugal1,155 1,257 Total$2,918